Dr. Immanuel Lerner, Ph.D. was appointed to Pepticom’s CEO in June 2014. He is a co-founder and a board member since 2013. Dr. Lerner has vast experience in neurobiology, immunology and cancer research specializing in the relations between inflammatory environment and cancer.
He is a trained biologist responsible for the design and oversee the laboratory validation of Pepticom’s technology. Dr. Lerner led and outlined the R&D project with ADAMA. Dr. Lerner holds M.Sc. in biochemistry with distinction and earned a Ph.D. followed by postdoctoral from the Hebrew University of Jerusalem.